- Stocks
- Healthcare
- NASDAQ: GBT

Price (delayed)

$42.60

Market cap

$2.65B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.04

Enterprise value

$2.38B

GBT's revenue is up by 46% since the previous quarter

Global Blood Therapeutics's gross profit has increased by 46% from the previous quarter

Global Blood Therapeutics's quick ratio has decreased by 15% YoY but it has increased by 4.4% QoQ

The debt has soared by 56% year-on-year and by 48% since the previous quarter

GBT's equity is down by 28% YoY and by 9% QoQ

What are the main financial stats of GBT

Market
Valuations
Earnings

Shares outstanding

62.16M

Market cap

$2.65B

Enterprise value

$2.38B

Price to earnings (P/E)

N/A

Price to book (P/B)

6.33

Price to sales (P/S)

21.1

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

19.21

Revenue

$123.8M

EBIT

-$237.74M

EBITDA

-$226.92M

Free cash flow

-$220.62M

Per share
Balance sheet
Liquidity

EPS

-$4.04

Free cash flow per share

-$3.6

Book value per share

$6.73

Revenue per share

$2.02

TBVPS

$11.8

Total assets

$724M

Total liabilities

$307.85M

Debt

$227.99M

Equity

$416.16M

Working capital

$553.13M

Debt to equity

0.55

Current ratio

8

Quick ratio

7.35

Net debt/EBITDA

1.19

Margins
Efficiency
Dividend

EBITDA margin

-183.3%

Gross margin

98.4%

Net margin

-200%

Operating margin

-197.2%

Return on assets

-34.4%

Return on equity

-52.3%

Return on invested capital

-57.3%

Return on capital employed

-36.9%

Return on sales

-192%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Global Blood Therapeutics stock price performed over time

Intraday

-2.07%

1 week

-11.86%

1 month

-10.3%

1 year

-34.68%

YTD

-1.64%

QTD

-1.64%

How have Global Blood Therapeutics's revenue and profit performed over time

Revenue

$123.8M

Gross profit

$121.82M

Operating income

-$244.16M

Net income

-$247.55M

Gross margin

98.4%

Net margin

-200%

Global Blood Therapeutics's operating margin has surged by 99% YoY and by 43% QoQ

The net margin has soared by 98% year-on-year and by 40% since the previous quarter

GBT's revenue is up by 46% since the previous quarter

Global Blood Therapeutics's gross profit has increased by 46% from the previous quarter

What is Global Blood Therapeutics's growth rate over time

What is Global Blood Therapeutics stock price valuation

P/E

N/A

P/B

6.33

P/S

21.1

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

19.21

The EPS has grown by 13% from the previous quarter and by 12% YoY

GBT's equity is down by 28% YoY and by 9% QoQ

The P/B is 27% above the 5-year quarterly average of 5.0 but 8% below the last 4 quarters average of 6.9

GBT's price to sales (P/S) is 75% lower than its last 4 quarters average of 83.5

GBT's revenue is up by 46% since the previous quarter

How efficient is Global Blood Therapeutics business performance

The ROS has soared by 98% YoY and by 41% from the previous quarter

The company's return on equity fell by 22% YoY but it rose by 4.6% QoQ

The ROA has grown by 10% from the previous quarter and by 6% YoY

The company's return on invested capital rose by 3.4% QoQ

What is GBT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for GBT.

How did Global Blood Therapeutics financials performed over time

Global Blood Therapeutics's total assets is 135% higher than its total liabilities

Global Blood Therapeutics's total liabilities has increased by 42% YoY and by 32% QoQ

Global Blood Therapeutics's quick ratio has decreased by 15% YoY but it has increased by 4.4% QoQ

The debt is 45% smaller than the equity

The debt to equity has soared by 120% YoY and by 62% from the previous quarter

The debt has soared by 56% year-on-year and by 48% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.